Okamoto A, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Itamochi H, Takano M, Takano T, Susumu N, Aoki D et al (2014) Gynecologic cancer intergroup (GCIG) consensus review for clear cell carcinoma of the ovary. Int J Gynecol Cancer 24:S20-25

Article  PubMed  Google Scholar 

Huang HJ, Yang LY, Tung HJ, Ku FC, Wu RC, Tang YH, Chang WY, Jung SM, Wang CC, Lin CT et al (2020) Management and clinical outcomes of patients with recurrent/progressive ovarian clear cell carcinoma. J Formos Med Assoc 119:793–804. https://doi.org/10.1016/j.jfma.2019.11.018

Article  PubMed  Google Scholar 

Tan DSP RT, Barrie C, et al. (2014) Analysis of outcomes in patients (pts) with recurrent ovarian clear cell carcinoma (ROCCC): time to rethink our approach to treatment. J Clin Oncol 32 (15_suppl): 5548

Lapke N, Chen CH, Chang TC, Chao A, Lu YJ, Lai CH, Tan KT, Chen HC, Lu HY, Chen SJ (2021) Genetic alterations and their therapeutic implications in epithelial ovarian cancer. BMC Cancer 21:499

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ku FC, Wu RC, Yang LY, Tang YH, Chang WY, Yang JE, Wang CC, Jung SM, Lin CT, Chang TC et al (2018) Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: results from a single-center Taiwanese study. J Formos Med Assoc 117:117–125. https://doi.org/10.1016/j.jfma.2017.03.007

Article  PubMed  Google Scholar 

Anglesio MS, Carey MS, Kobel M, Mackay H, Huntsman DG, Vancouver Ovarian Clear Cell Symposium S (2011) Clear cell carcinoma of the ovary: a report from the first ovarian clear cell symposium, June 24th, 2010. Gynecol Oncol 121:407–415. https://doi.org/10.1016/j.ygyno.2011.01.005

Article  PubMed  Google Scholar 

Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA et al (2017) An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: an NRG oncology/gynecologic oncology group experience. Gynecol Oncol 147:243–249. https://doi.org/10.1016/j.ygyno.2017.08.004

Article  PubMed  PubMed Central  Google Scholar 

Bolton KL, Chen D, Corona de la Fuente R, Fu Z, Murali R, Kobel M, Tazi Y, Cunningham JM, Chan ICC, Wiley BJ et al (2022) Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes. Clin Cancer Res 28:4947–4956

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen J, Peng Y, Wei L, Zhang W, Yang L, Lan L, Kapoor P, Ju Z, Mo Q, Shih IeM et al (2015) ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Cancer Discov 5:752–767. https://doi.org/10.1158/2159-8290.CD-14-0849

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amano T, Chano T, Yoshino F, Kimura F, Murakami T (2019) Current position of the molecular therapeutic targets for ovarian clear cell carcinoma: a literature review. Healthcare. https://doi.org/10.3390/healthcare7030094

Article  PubMed  PubMed Central  Google Scholar 

Zhou P, Wang J, Mishail D, Wang CY (2020) Recent advancements in PARP inhibitors-based targeted cancer therapy. Precis Clin Med 3:187–201

Article  PubMed  PubMed Central  Google Scholar 

Kohn EC, Lee JM, Ivy SP (2017) The HRD decision-which PARP inhibitor to use for whom and when. Clin Cancer Res 23:7155–7157

Article  PubMed  PubMed Central  Google Scholar 

Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G et al (2019) Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381:2391–2402. https://doi.org/10.1056/NEJMoa1910962

Article  CAS  PubMed  Google Scholar 

Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Keeton EK, Wang P, Gupta D, Clements A et al (2022) OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol 166:219–229. https://doi.org/10.1016/j.ygyno.2022.05.020

Article  CAS  PubMed  Google Scholar 

Backes FJ, Wei L, Chen M, Hill K, Dzwigalski K, Poi M, Phelps M, Salani R, Copeland LJ, Fowler JM et al (2021) Phase i evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol 162:619–625. https://doi.org/10.1016/j.ygyno.2021.06.032

Article  CAS  PubMed  Google Scholar 

Cabanillas ME, Habra MA (2016) Lenvatinib: role in thyroid cancer and other solid tumors. Cancer Treat Rev 42:47–55

Article  CAS  PubMed  Google Scholar 

Ye J, Qi L, Liang J, Zong K, Liu W, Li R, Feng R, Zhai W (2021) Lenvatinib induces anticancer activity in gallbladder cancer by targeting AKT. J Cancer 12:3548–3557

Article  CAS  PubMed  PubMed Central  Google Scholar 

Makker V, Colombo N, Casado Herraez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I et al (2022) Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 386:437–448. https://doi.org/10.1056/NEJMoa2108330

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kawahara N, Yamada Y, Kobayashi H (2021) CCNE1 is a putative therapeutic target for ARID1A-mutated ovarian clear cell carcinoma. Int J Mol Sci. https://doi.org/10.3390/ijms22115869

Article  PubMed  PubMed Central  Google Scholar 

Pacheco-Barcia V, Munoz A, Castro E, Ballesteros AI, Marquina G, Gonzalez-Diaz I, Colomer R, Romero-Laorden N (2022) The homologous recombination deficiency scar in advanced cancer: agnostic targeting of damaged DNA repair. Cancers (Basel). https://doi.org/10.3390/cancers14122950

Article  PubMed  Google Scholar 

Tan TZ, Ye J, Yee CV, Lim D, Ngoi NYL, Tan DSP, Huang RY (2019) Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes. EBioMedicine 50:203–210

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah MM, Dobbin ZC, Nowsheen S, Wielgos M, Katre AA, Alvarez RD, Konstantinopoulos PA, Yang ES, Landen CN (2014) An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. Gynecol Oncol 134:331–337

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kwok AL, Wong OG, Wong ES, Tsun OK, Chan KK, Cheung AN (2014) Caution over use of ES2 as a model of ovarian clear cell carcinoma. J Clin Pathol 67:921–922

Article  CAS  PubMed  Google Scholar 

Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ et al (2009) mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 15:5404–5413. https://doi.org/10.1158/1078-0432.CCR-09-0365

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chao A, Lin CY, Wu RC, Lee YS, Lee LY, Tsai CL, Yang LY, Liu H, Chen SJ, Wang TH et al (2018) The combination of everolimus and terameprocol exerts synergistic antiproliferative effects in endometrial cancer: molecular role of insulin-like growth factor binding protein 2. J Mol Med (Berl) 96:1251–1266. https://doi.org/10.1007/s00109-018-1699-5

Article  CAS  PubMed  Google Scholar 

Lin CY, Wu RC, Huang CY, Lai CH, Chao AS, Li HP, Tsai CL, Kuek EJ, Hsu CL, Chao A (2021) A patient-derived xenograft model of dedifferentiated endometrial carcinoma: a proof-of-concept study for the identification of new molecularly informed treatment approaches. Cancers (Basel). https://doi.org/10.3390/cancers13235962

Article  PubMed  PubMed Central  Google Scholar 

Sun K, Mikule K, Wang Z, Poon G, Vaidyanathan A, Smith G, Zhang ZY, Hanke J, Ramaswamy S, Wang J (2018) A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. Oncotarget 9:37080–37096

Article  PubMed  PubMed Central  Google Scholar 

Kopper O, de Witte CJ, Lohmussaar K, Valle-Inclan JE, Hami N, Kester L, Balgobind AV, Korving J, Proost N, Begthel H et al (2019) An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med 25:838–849. https://doi.org/10.1038/s41591-019-0422-6